First-of-its-Kind DNA Biobank Opens in Peru
First-of-its-Kind DNA Biobank Opens in Peru
Back to Newsroom

First-of-its-Kind DNA Biobank Opens in Peru

A significant milestone was reached for both the nation of Peru and the Global Parkinson’s Genetics Program (GP2).

Peru’s Instituto Nacional de Ciencias Neurológicas celebrated the opening of its DNA biobank, the first of its kind in Peru. The biobank will serve as a repository for genetic samples, implementing a system and standards for the use of genetic information for research at the Institute as well as other national and international collaborators. 

Development of the DNA biobank was made possible with support from ASAP, the Michael J. Fox Foundation, and LARGE-PD. With the infrastructure portion of the bank nearly complete, ASAP helped commemorate the opening ceremony virtually with colleagues in Peru.

ASAP—through its Global Parkinson’s Genetics Program—seeks to understand the genetics that contribute to PD in Latin America and around the world. The DNA biobank marks an important step to facilitate Parkinson’s disease research in-country and helps ASAP and partners get closer to the goal of global representation for GP2 research. 

Learn more about GP2 and submit a cohort here.

Related Content

Acting out dreams may signal health conditions, including Parkinson’s

Read this article from The Washington Post on how REM sleep behavior disorder (RBD) can be a sign of early-onset Parkinson’s disease and how the Michael J. Fox Foundation is inviting people who act out their dreams to participate in the Parkinson’s Progression Markers Initiative (PPMI).

Neuronal diversity impacts the brain’s information processing

This news story features Team Surmeier’s findings related to the impact of neuronal structural diversity on neural computation, the basis of brain function.

New framework for Parkinson’s stages is based on disease biology

Parkinson’s News Today reports on The Michael J. Fox Foundation For Parkinson’s Research’s (MJFF) proposed framework for defining and staging PD-based on its underlying biology rather than by hallmark disease symptoms.